Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial

Detalles Bibliográficos
Autores principales: Garcia-Manero, Guillermo, Mufti, Ghulam J., Fenaux, Pierre, Buckstein, Rena, Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Ilhan, Osman, Sekeres, Mikkael A., Zeidan, Amer M., Ito, Rodrigo, Zhang, Jennie, Rampersad, Anita, Sinsimer, Daniel, Backstrom, Jay T., Platzbecker, Uwe, Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796653/
https://www.ncbi.nlm.nih.gov/pubmed/34758066
http://dx.doi.org/10.1182/blood.2021012589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796653/
https://www.ncbi.nlm.nih.gov/pubmed/34758066
http://dx.doi.org/10.1182/blood.2021012589

Ejemplares similares